https://slenterprise.com/index.php/news/7714-industry-briefs-10-21-24
RECOGNITIONS
- This year’s PharmaVoice 100 honorees list includes David Bearss, CEO, president and co-founder of Halia Therapeutics, a Lehi-based company developing therapies addressing chronic inflammation. Bearss has more than 20 years of experience in drug development. He has launched eight companies, including Tolero Pharmaceuticals, which was sold to Sumitomo Dainippon in 2016.